---
run_id: halo-evidence-vs-diagnosis-validation-v12-famous-sources-supplied-08
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
model_condition: famous_sources_supplied
run_number: 8
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 2048
seed: 802
prompt_source: condition packet (famous_sources_supplied) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
source_packet: a name-level list of famous source titles and authors, then the frozen Advisor prompt; no benefits cases, summaries, source cards, or tension card - see run-packet.md
source_packet_sha256: fbda9621700ea5a031af698b8700a95ac925370d84a60c86c1d7bce543e8cc3b
condition_packet_sha256: fbda9621700ea5a031af698b8700a95ac925370d84a60c86c1d7bce543e8cc3b
output_file: model-outputs/famous_sources_supplied-08.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - famous_sources_supplied (run 08)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v12-v1`, condition `famous_sources_supplied`, run 8 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 802, on the frozen condition packet.

## Output

**Recommendation:** Commit to the **Case Evidence Review**.

**Why:**
Your current success metrics are "entangled" and likely misleading. The rise in expansion bookings is driven by pricing incentives (bundle discounts), not necessarily product value. Usage data is skewed by managers rerunning samples rather than analysts solving live problems. Most critically, the "silent churn" from regional administrators and the abandonment in the public sector suggest a fundamental gap between the tool's output and the user's ability to execute or justify that output.

The Case Evidence Review is the only option that addresses the *causal* mechanism of value. By inspecting whether suggestions are accepted, overridden, or "impossible to explain," you move from vanity metrics (usage/bookings) to evidence of product-market fit. This prevents the company from scaling a feature that users are currently "hacking" or avoiding, which would otherwise lead to a massive churn event once the bundle pricing expires and procurement windows close.

**The strongest reason against it:**
It is a slow, qualitative process that does not provide the immediate "hard numbers" (like the Demand Cleanroom or Adoption Quality Sprint) that a Board typically wants to see twelve days before locking a budget. It risks being viewed as "anecdotal" compared to the quantitative allure of the Adoption Quality Sprint.

**Observable evidence that would change my mind:**
If the "Demand Cleanroom" results were to show that renewal rates and expansion intent remain identical even without the bundle pricing and roadmap pitches, it would prove that the commercial momentum is organic. In that scenario, the risk shifts from "product failure" to "growth optimization," making the Demand Cleanroom or scaling the product a more urgent priority than deep-dive case evidence.
